Survodutide and Wegovy both use the GLP-1 pathway to reduce appetite, but they aren’t in the same place. Wegovy (semaglutide) is FDA approved and available now, with years of data behind it. Survodutide is investigational, still in Phase 3 trials, and adds a second hormone (glucagon) that raises energy burn and targets liver fat. Survodutide’s standout is its effect on fatty liver disease, while Wegovy’s strength is a proven, long-term track record. Neither survodutide’s availability nor its final results are settled yet, and it can’t be prescribed or bought, including through TrimRx.<\/p>\n
Wegovy is semaglutide 2.4 mg, a once-weekly GLP-1 injection FDA approved in 2021 for weight management. It reduces appetite and slows gastric emptying. In its main trial, it produced about 15% average weight loss over 68 weeks, with two-year data showing that loss was largely sustained<\/a> for people who continued treatment.<\/p>\n Semaglutide also has proven benefits beyond weight: it has been shown to improve outcomes in obesity-related conditions, including heart failure with preserved ejection fraction in people with obesity. The common side effects are gastrointestinal (nausea affects roughly 44% of users, usually early and mild to moderate). The key point is that Wegovy is available and well understood today.<\/p>\n Survodutide (code BI 456906) is an investigational once-weekly injection from Boehringer Ingelheim and Zealand Pharma that activates two receptors: GLP-1 and glucagon. GLP-1 suppresses appetite (like semaglutide), while glucagon raises energy expenditure and drives the liver to burn fat. This dual design is also why survodutide is often compared to tirzepatide<\/a>, which adds a different second hormone.<\/p>\n In its Phase 2 obesity trial, survodutide produced about 15% weight loss at 46 weeks (and close to 19% in the on-treatment analysis), with the curve still descending at the end, hinting at potentially larger loss over a full course. Its most striking results came in a Phase 2 MASH (fatty liver) trial, where it improved liver fibrosis and sharply reduced liver fat. Survodutide is in Phase 3 for both obesity and liver disease, with a careful titration schedule<\/a> and a possible FDA submission in 2026 or later.<\/p>\n Wegovy works through GLP-1 alone. Survodutide adds glucagon, aiming to burn more energy and mobilize liver fat on top of appetite suppression. In theory, the second hormone could push weight loss higher, but survodutide hasn’t finished Phase 3, so its real-world advantage over semaglutide isn’t proven yet.<\/p>\n On the data available, the two look broadly comparable on weight, with survodutide’s Phase 2 numbers landing near Wegovy’s, and possibly trending higher with longer treatment. But Wegovy’s figures come from large, completed trials, while survodutide’s come from a smaller, earlier study. Wegovy has the settled evidence.<\/p>\n This is survodutide’s distinctive angle. Its glucagon activity targets liver fat, which is why its MASH results stand out. Wegovy has its own emerging role in liver disease, but survodutide was designed with hepatic effects front and center. For fatty liver specifically, survodutide is the more targeted candidate, though it remains unavailable.<\/p>\n This is the deciding factor for most people. Wegovy can be started today. Survodutide is still in trials, with approval possibly in 2027 to 2028 at the earliest. Waiting for survodutide means delaying treatment for years on the chance it proves better, while Wegovy’s benefits are available right now.<\/p>\n Survodutide is investigational and still in Phase 3, so it can’t be prescribed, and there’s no legal compounded version (compounding applies to approved drugs). Peptides marketed online as survodutide have no oversight on purity, sterility, or dosing and aren’t a safe or legal substitute. The trial doses described here are what researchers used under supervision, not a routine to copy at home.<\/p>\n While survodutide moves through development, Wegovy is one of several effective, approved options you can begin today. A licensed provider can help you decide whether semaglutide fits your health history and goals, or whether another medication is a better match. The benefits of treatment add up while you wait, not after, and switching to a newer drug later is straightforward if one proves worthwhile.<\/p>\nWhat Is Survodutide?<\/h3>\n
Survodutide vs Wegovy at a Glance<\/h3>\n
\n\n
\n \nFeature<\/th>\n Survodutide<\/th>\n Wegovy (semaglutide)<\/th>\n<\/tr>\n<\/thead>\n \n Status<\/td>\n Investigational<\/td>\n FDA approved (2021)<\/td>\n<\/tr>\n \n Available now?<\/td>\n No<\/td>\n Yes<\/td>\n<\/tr>\n \n Mechanism<\/td>\n GLP-1 + glucagon<\/td>\n GLP-1 only<\/td>\n<\/tr>\n \n Standout feature<\/td>\n Liver (MASH) benefits<\/td>\n Proven long-term track record<\/td>\n<\/tr>\n \n Weight loss<\/td>\n ~15% to 19% at 46 weeks (Phase 2)<\/td>\n ~15% at 68 weeks (Phase 3)<\/td>\n<\/tr>\n \n Earliest availability<\/td>\n ~2027-2028 or later<\/td>\n Available today<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n The Key Differences<\/h3>\n
One hormone or two<\/h4>\n
Weight loss<\/h4>\n
Liver disease<\/h4>\n
Available now versus years away<\/h4>\n
Why Survodutide Isn’t Available Yet<\/h3>\n
Starting Treatment Now<\/h3>\n